EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Coden USA: EJBPBO
Volume: 12
Issue: 11
Year: 2025

BIOSIMILARS FOR CANCER CARE: REGULATORY PATHWAYS, CLINICAL EVIDENCE, AND THE ROLE OF FILGRASTIM AND PEGFILGRASTIM

Sampath Sri Venkata Sai Kumar Maddula[1], Swetha Vegesna[1]*, Naga Datta Sasi Mrudula Kothapalli[1], Mishall Masa[1]

Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences and Technologies JNTUK Kakinada – 533003, Andhra Pradesh, India.

***Corresponding Author: Swetha Vegesna**
Department of Pharmaceutical Analysis, School of Pharmaceutical Sciences and Technologies JNTUK Kakinada – 533003, Andhra Pradesh, India.

DOI: https://doi.org/10.5281/zenodo.17539449

How to cite this Article: Sampath Sri Venkata Sai Kumar Maddula1, Swetha Vegesna1*, Naga Datta Sasi Mrudula Kothapalli1, Mishall Masa1. (2025). BIOSIMILARS FOR CANCER CARE: REGULATORY PATHWAYS, CLINICAL EVIDENCE, AND THE ROLE OF FILGRASTIM AND PEGFILGRASTIM. European Journal of Biomedical and Pharmaceutical Sciences, 12(11), 219–229.

Article Received on 10/10/2025 **Article Revised on 31/10/2025** **Article Published on 01/11/2025**

ABSTRACT

Biosimilars are biopharmaceuticals designed to demonstrate a high degree of similarity to reference biologics, guaranteeing no significant differences in safety, purity, or effectiveness. Due to the intricate nature of biologics, the development of biosimilars demands sophisticated analytical characterization, functional validation, and confirmatory preclinical and clinical trials. In contrast to small-molecule generics, proving biosimilarity involves more than just chemical equivalence; it also encompasses similar pharmacokinetic, pharmacodynamic, and immunogenicity profiles. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented rigorous approval processes, bolstered by long-term monitoring of drug effects, to ensure therapeutic reliability and patient safety. Oncology is a significant field for the adoption of biosimilars. Biosimilars for supportive care medications like filgrastim and pegfilgrastim have demonstrated comparable efficacy and safety to their original biologics in preventing neutropenia caused by chemotherapy. Their incorporation into cancer treatment has lowered costs, improved access in both advanced and developing areas, and supported more sustainable approaches to cancer management. This review brings together the evolution, structural and functional assessment, regulatory frameworks, manufacturing aspects, and clinical verification of biosimilars. With an emphasis on applications in oncology, particularly filgrastim and pegfilgrastim, the data highlights their crucial role in enhancing sustainable healthcare and increasing access to high-quality cancer therapies globally.

KEY WORDS: Biosimilars, Pharmacokinetics, Pharmacodynamics, Monoclonal antibodies, Interchangeability.

INTRODUCTION

Biologic medications produced by a different business that are almost identical to the original product or FDA-approved reference biological are known as biosimilars. However, because biological products are manufactured using cell lines specific to a particular manufacturer and undergo a number of purification procedures, biosimilars are not exact replicas. Despite this, the clones and the original biologic are fairly similar. A similar biologic, according to the Drug Controller General of India (DCGI), is a biological medication made by genetic engineering that is said to closely resemble a reference biologic that has been authorised for safe use in terms of efficacy, safety, and quality. The US Food and Drug Administration (FDA) defines biologics as complex compounds produced by biotechnology inside living systems, such as plant, animal, and microbial cells. The United States uses a wide variety of biological products, such as monoclonal antibodies, therapeutic proteins, and certain vaccinations. Early control over the development of new, comparable biological products was necessary to address the pertinent problems facing the industry. There has been intense competition in the pharmaceutical sector ever since biosimilars were first released in the biotechnology sector in 2006. Since then, the EMA has authorised the sale of over 50 biosimilars. In 2013, the EU authorised the first monoclonal antibody biosimilar, a replica of Infliximab. On March 6, 2015, the FDA

authorised Sandoz's filgrastim/sndz (tradename Zarxio), a biosimilar to filgrastim. Sandoz released guidelines for evaluating similar biopharmaceutical medications (SBP'S in 2009**).** This guideline's objective is to establish a global standard for assessing biosimilars.

An analytical bio-similarity analysis is carried out to demonstrate that the biosimilar product's variations in important quality characteristics (CQAs) have a very similar profile and fall within the range set by the original. To determine how similar the molecules are to one another, a profile is created utilising a range of analytical methods, including as CD spectroscopy, isoelectric focussing, mass spectrometry, capillary electrophoresis, HPLC (high-performance liquid chromatography), and ramen spectrometry. Due to its low throughput, high sample consumption, or laborious data analysis, this approach is not very well suited for rapidly screening a large number of biosimilar candidates, even though it is useful for comprehensively characterising biosimilar candidates.

Nano DSF (Nano Differential Scanning Fluorimetry) provides highly presiden and repeatable detection of thermal unfolding patterns to accurately recreate structural stability and similarity between diverse unfolding processes. To reduce the number of candidates for the biosimilar development process, a large number of biosimilar radiants in various stages of development can be quickly screened using the nano thermal unfolding profiling technique.

Analytical platforms are typically employed in process management and monitoring, and they are crucial to the creation of biopharmaceuticals and related goods. Because biologicals contain active proteins, they are more likely to trigger an immunological response, both acute and chronic. Despite the low overall risk of biosimilars, regulatory channels are required due to the manufacturing process, structural complexity, and immunogenicity risk. Biosimilars provide safe and effective treatment options for a variety of conditions, such as cancer, rheumatoid arthritis, renal issues, and chronic skin and gastrointestinal conditions like psoriasis, IBS, Crohn's disease, and colitis. Biosimilars expand access to potentially life-saving, lower-cost drugs. One of the biotechnology industry's fastest-growing segments at the moment is biopharmaceuticals. The biologics industry has undergone tremendous change in the last ten years. At a compound annual growth rate of 9.5% (2018–2026), its market value, which was USD 254.9 billion in 2017, is projected to reach USD 518.5 billion by 2026 (global-2018). 200 approved biosimilars are currently available for purchase.[1,2,3,4,5]

ORIGIN AND EVALUATION OF BIOSIMILARS

The idea of biosimilars was born out of the growing need for less expensive substitutes for innovative biologics, particularly following the expiration of the patents on a number of popular medications. In 2005, the European Medicines Agency (EMA) set a global standard for the approval of biosimilars by being the first regulatory authority to create a framework for them.

The first biosimilar in history, somatropin, a recombinant human growth hormone, was approved by the European Medicines Agency (EMA) in 2006. This historic approval showed that it is possible to create safe and efficient substitutes for reference biologics. The first monoclonal antibody biosimilar, infliximab, was approved by the European Medicines Agency (EMA) in 2013, thereby broadening the range of biosimilars to include complex therapeutic proteins used in autoimmune and oncological conditions.

Other regulatory bodies across the world implemented biosimilar criteria after the EMA did. The FDA released its draft guidance in 2012, opening the door for biosimilar approvals. The Biologics Price Competition and Innovation (BPCI) Act of 2009 created a legislative foundation for biosimilars in the US. While India, Korea, and a number of other nations created their own regulatory frameworks to promote domestic biosimilar development, Japan established the idea of "follow-on biologics."

By publishing guidelines to standardise biosimilar laws across nations, the World Health Organisation (WHO) also made a substantial contribution. Together, these international initiatives facilitated the expansion of the biosimilar market, increasing its accessibility and availability to patients across various geographies.

Since their beginnings, biosimilars have been crucial in improving patient access to life-saving biologics and lowering healthcare costs. The biosimilar development pathway has been reinforced by the ongoing development of analytical technology, regulatory standards, and manufacturing procedures, guaranteeing the efficacy, safety, and quality of the final product.[6,7,8,9]

Table 1: Differences between Generics and Biosimilars.[10,11,12,13]

Aspect	Generics (Small-Molecule Drugs)	Biosimilars (Large-Molecule Biologics)
Molecular nature	Chemically synthesized, small molecules	Biotechnologically derived, large, complex proteins
Structural characteristics	Identical chem[ical copies of the reference drug	Highly similar but not identical; natural variability expected
Manufacturing process	Simple, reproducible, and well-defined chemical synthesis	Complex, cell-based production; sensitive to cell line, culture, and purification variations

Product variability	Minimal; structure and activity can be exactly replicated	Inherent variability due to biological processes (glycosylation, folding, post-translational modifications)
Regulatory approval pathway	Abbreviated New Drug Application (ANDA,505(j)), requiring bioequivalence studies	Biologics License Application(351(k)),requiring stepwise comparability including analytical, non-clinical, and clinical evaluations
Evaluation focus	Bioequivalence via pharmacokinetics (PK); limited clinical data	Comprehensive: analytical characterization, PK/PD, immunogenicity, and clinical safety/efficacy studies
Auto-substitution	Pharmacists can substitute without prescriber input	Requires designation of "interchangeability"; additional studies often needed
Overall distinction	Exact, cost-effective replicas of small-molecule drugs	Highly similar, rigorously validated alternatives to complex biologics, with stricter regulatory oversight

Creating and examining biosimilars

Step 1: The development of the biosimilar necessitates scientific and manufacturing understanding because biological drugs have complex structures. To create a biosimilar, the manufacturer must show that they comprehend how biological medications work in the body. The developer should concentrate on developing its own method for making biosimilars rather than keeping confidential information regarding the production process of biological medications.

Step 2: Biological and biosimilar product development Both the biosimilar and the original biological products are produced using a number of methods that are specific to each manufacturer. There will therefore be a slight variance in the finished goods. In living cells, the process is multi-step. A small change in manufacturing details could affect the products' quality, safety, and effectiveness. It is important to detect the changes and demonstrate that they are not clinically significant, even if the biosimilar is expected to be safer and more effective than the original biological drug.

Step 3: The biological drug is quite complex and has many properties. In biology, there are a hundred or more attributes. A few traits are important in many different ways. For instance, the safety, efficacy, and pharmacokinetic characteristics of the drug may depend on the body's capacity to recognise the present protein. These functions' essential attributes are frequently called their characteristics (CQA). This CQA includes a wide range of molecular structural features that are affected by the cell line, DNA, and manufacturing process. Since critical quality characteristics (CQAs) may affect clinical activity—the way a chemical affects a patient—they should fall within the expected range. The manufacturer of the biosimilar uses more than 40 analytical techniques to find 100 characteristics.

Step 4: Among the several tests performed to show that a biosimilar medication differs significantly from the original biological medication are preclinical assays and clinical evaluations. An evaluation known as the totality of the evidence is produced by combining all data from analytical, nonclinical, and clinical research. Some of the tests that go into this totality of evidence are as follows.[14,15,16,17]



Figure 1: Evaluation of Biosimilars.

Structures

2.2 Recent Advancements and Orthogonality in Analytical Similarity Assessment



Figure 2: Steps involved in formation of Biosimilars.

Structures

1.1 Recent Advancements and Orthogonality in Analytical Similarity Assessment

According to USFDA guidelines, biosimilar characterisation should be done using orthogonal analytical methodologies because no single tool can capture all essential quality attributes (CQAs). Regular biosimilarity evaluations have been enhanced over time by the addition of several sophisticated biophysical and statistical methods. Peptide mapping, glycan profiling, charge variants, size variants, and higher-order structure (HOS) and stability are the most often discussed topics in publications.

1.1.1 Primary structure

Because of its greater sensitivity and resolution, Edman degradation or, more frequently, mass spectrometry (MS) are used to confirm sequence and mass identity.

Under non-denaturing circumstances, intact mass and HOS assessment are made possible by native MS (SEC-MS, IM-MS, HDX-MS).

With the use of Orbitrap and QTOF systems, fragmentation methods (ECD, HCD, and CID), and stable isotope labelling, peptide mapping has progressed to nearly full sequence coverage.

With growing application in QC, multi-dimensional LC (2D-LC) and multi-attribute methods (MAM) now provide comprehensive analysis at the whole, subunit, and peptide levels.

With the aid of chemometric techniques, MALDI-TOF-MS provides quick, salt-tolerant analysis for peptide mapping and disulphide bridging.

1.1.2 Higher-Order Structure (HOS)

For secondary, tertiary, and quaternary structural analysis, orthogonal methods are crucial. Secondary: Computational deconvolution has improved the widely used Far-UV CD and FTIR. Tertiary: While near-UV CD and fluorescence are still frequently used, NMR (1D/2D) and HDX-MS have become industry standards, offering atomic-level understanding of protein dynamics and structure. Conformational stability: Thermal unfolding and stability evaluation are common uses for DSC, nanoDSF, and CIU-MS.

1.1.3 Glycosylation

Using LC-MS and HILIC-FLD/MS, glycan profiling entails multi-level analysis (intact, glycopeptide, released glycans), supported by innovative labels such as RapiFluor-MS.

Among the orthogonal approaches are lectin microarrays, spectroscopic methods (FTIR, NMR, Raman), CE (CZE, CGE), and HPAEC-PAD.

Advanced software (GUcal, MoFi) improves data interpretation and glycan labelling.

1.1.4 Product-Related Variants and Impurities

Other PTMs, charge heterogeneities, and size (aggregates/fragments) are examples of variations. The aggregates SEC-UV/MALS, AUC, CE-SDS, LO, MFI, DLS, AF4, and sophisticated instruments including DOSY-NMR, EM-based techniques, and NTA are used for assessment.

Charge variations: The gold standard is CEX, while CE provides an orthogonal high-resolution substitute.[18,19,20,21,22,23]



Figure 3: Techniques used in Biosimilars.

Interchangeability

A product feature known as interchangeability enables a biosimilar to be used in place of its reference biologic while still providing the same clinical result. According to Haustein et al. (2014), this can happen through automated substitution, in which a chemist dispenses a substitute medication without first consulting the physician, or switching, in which a prescriber makes a change based on therapeutic aim. Although regulatory bodies such as the WHO and EMA support the scientific rationale for substitution, they frequently leave the choice to switch to national organisations or individual doctors (GABI, 2023). The safety and effectiveness of more than 100 biosimilars across all legal indications have been confirmed by the European Union over the course of over 20 years. Nonetheless, switching can be further divided into non-medical and medical categories. Clinical considerations like adverse effects or ease of administration can lead to medical switching. For instance, in trials, biosimilar TNF inhibitors were linked to fewer injection site reactions, which may have been caused by variations in excipients and packaging materials (Haustein et al., 2014). On the other hand, supply or pricing concerns frequently motivate non-medical switching. Instead of using automated substitution, professional associations in the USA, Canada, Europe, and Australia constantly stress that the treating physician should make the decision to switch, frequently after consulting with the patient (Haustein et al., 2014). Before granting the "interchangeable" designation, the U.S. FDA needs a rigorous study design that includes a two-arm randomised trial in which one arm swaps between the reference medicine and the biosimilar at least three times while the other arm stays on the reference drug. No clinically significant variations in immunogenicity, pharmacokinetics, effectiveness, or safety between groups are to be shown (Lucero et al., 2022). Insulin glargine-yfgn is the only biosimilar insulin that has been given an interchangeability label thus far. This is because the INSTRIDE-3 trial demonstrated that the biosimilar and Lantus were similarly safe, effective, and immunogenic (Lucero et al., 2022). Given that insulin has a simpler structure than other biologics, the FDA updated its guidelines in 2019 to permit approval under the 351(k) pathway without a comparative clinical immunogenicity study, as long as the biosimilar claim is supported by strong analytical data and little residual uncertainty (Lucero et al., 2022; Tischer & Machacek, 2019).[24,25,26,27]

Approvals and Guidelines

Table 2: Approval and guidelines.[28,29,30,31,32,33,34]

Aspect	INDIA(CDSCO/DCGI)	EMA(Europe)	FDA(USA)	WHO	JAPAN
Year introduced	Established early 2010	2005(first biosimilar guidelines)	2009(via BPCI act)	2009(guidelines published)	2009(follow-on-biologics concept)
Regulatory body	CDSCO & DCGI with department of biotechnology	EMA-CHMP	FDA –center for drug evaluation and research (CDER)	WHO expert committee on biologics	PMDA(pharmaceutical and medical device agency)
Approval basis	Comparability exercise (physicochemical, Nonclinical, clinical)	Stepwise comparability (analytical ,non-clinical, clinical)	Step wise approach with flexibility depending upon similarity	Stepwise approach for global immunization	Based on ICH guidelines and bridging studies if needed
Nonclinical requirements	Mandatory; toxicity, allergenicity, tolerance studies	Required as a part of step wise approach	Included as needed based on risk assessment	Recommended based on risk and comparability	Required extensive analytical and functional studies
Clinical trials	Mandatory; phase 3, therapeutic equivalence and immunogenicity studies	Required class specific guidelines for step wise approach	Required; includes PK/PD ,safety,immuniogenicity	Emphasized for safety and efficacy	Required with possibility of bridging studies
interchangeability	Not formally defined	Not automatically granted, country-level	Specific designation, require additional data	Not directly addressed –based on national authorities	Not designes,substitution is not automatic
Post marketing requirements	Mandatory PSURs,risk management plan and pharmacovigilance studies	Required-including risk management and pharmacovigilance studies	Required-especially for interchangeable biosimilars	Strongly emphasized important for global surveillance	Mandatory safety monitoring
Class –specific guidelines	Not well developed across all biologic's sites	Present-eg-mAbs,insulin ,growth harmones	Product-class specific considerations in guidelines	Generalized guidelience,not class specific	Not fully class specific,but aligned with ICH
Development flexibility	Moderate-follow structure national guidelines	High-allows scientific dissection within defined comparability principles	High-permits tailoring based on data quality and similarity	Guideline support adaptability for resource lmited settings	Moderate, flexible with ICH
Global influence	Inspired by EMA &WHO	Considered the global pioneer in biosimilar regulation	Influence some north American and latin American countries	Reference framework for many low- and middle-income countries	Regionally influenced in Asia-pacific

Biosimilars in Oncology

Only a small number of biosimilars are currently authorised for the treatment of cancer and supportive care. For monoclonal antibodies (mAb) such as Rituximab, Trastuzumab, and Bevacizumab, as well as supportive drugs including filgrastim, pegfilgrastim, epoetin α, and epoetin ζ, biosimilars are available.

Pegfilgrastim and filgrastim

The FDA authorised Zarxio® (filgrastim-sndz) in March 2015, making it the first biosimilar medication ever to be marketed in the United States. 51 Both of these biosimilars can be used for the same indications as the reference medication, Neupogen® (Filgrastim), while Nivestym® (filgrastim-aafi) was approved later in 2018. 52 A recombinant granulocyte colony-stimulating factor (G-CSF) called filgrastim controls the bone marrow's production of neutrophils. In patients with non-myeloid cancers undergoing myelosuppressive anticancer medications or myeloablative chemotherapy followed by bone marrow transplantation, filgrastim is used to lessen febrile neutropenia. It is also used to shorten the length of fever and the time it takes for neutrophils to recover in patients with acute myeloid leukaemia after induction or consolidation chemotherapy. 53 The European Medicines Agency (EMA) has approved nine biosimilars of Filgrastim in Europe: Accofil®, Biograstim®, Filgrastim Hexal®, Filgrastim Ratiopharm®, Grastofil®, Nivestim®, Ratiograstim®, Tevegrastim®61, and Zarzio®. 62. At the request of the holders of the corresponding marketing authorisations, the EMA did, however, discontinue the marketing of Biograstim® and Filgrastim Ratiopharm®. 55 and 57 Pegfilgrastim and lenograstim are two further G-CSFs that are frequently used to treat chemotherapy-induced neutropenia (CIN). Pegfilgrastim is a long-acting G-CSF that is given once every chemotherapy cycle, whereas filgrastim and lenograstim are short-acting G-CSFs that are injected daily during chemotherapy. 63 Pegfilgrastim's half-life is extended by the presence of an extra polyethylene glycol unit, which makes the molecule much larger. 64 As shown in Figure 1, filgrastim, pegfilgrastim, lenograstim, and all biosimilars work to boost neutrophil maturation and proliferation after binding to G-CSF receptors,

lowering the risk of neutropenia. JAK3 translocates to the nucleus as a result of the activation of the JAK–STAT signalling pathway. As shown in Figure 2, JAK3 attaches to DNA once it is inside the nucleus and triggers transcription related to neutrophil proliferation65. Europe has eight approved biosimilars of pegfilgrastim: Nyvepria®, Pelgraz®, 66 Udenyca®, 67 Fulphila®, 68 Pelmeg®, 69 Ziextenzo®, 70 Grasustek®, 71 Cegfila®, and 72. 73 In contrast, four biosimilars of Neulasta® (pegfilgrastim) have been licensed in the United States: Nyvepria® (pegfilgrastim-apgf), Fulphila® (pegfilgrastim-jmdb), Udenyca® (pegfilgrastim-cbqv), and Ziextenzo® (pegfilgrastim-bmez). 77 There are currently no lenograstim biosimilars on the market.



Figure 1: An illustration of how filgrastim, pegfilgrastim, and related biosimilars interact with granulocyte colony stimulating factor receptors.



Figure 2: The mechanism of action of filgrastim, pegfilgrastim, and its biosimilars. The JAK–STAT signalling system promotes survival, proliferation, and differentiation after it binds to the granulocyte colony stimulating factor receptor.

Table 3: List of Biosimilars.[35,36,37,38,39,40]

S.NO	BIOSIMILAR	API	YEAR OF APPROVAL	COMPANY
1	Versavo	Bevacizumab	2019	Dr.Reddy's Labratories
2	Hervycta	trastuzumab	2018	Dr.Reddy's Labratories
3	Pegfilgrastim	Pegfilgrastim	2018	Lupin
4	Fulphile	Pegfilgrastim	2018	Biocon Ltd
5	Acellbia	Rutuximab	2017	Biocad
6	Krabeva	bevacizumab	2017	Biocon
7	Bevacirel	Bevacizumab	2016	Reliance life sciences
8	Cizumab	Bevacizumab	2016	Hetero group
9	Maball	Rituximab	2015	Hetero group
10	Rituxirel	Rituximab	2015	Reliance life sciences

Analytical and Bioanalytical Challenges in Biosimilar Development

In order to show resemblance to the reference biologic, biosimilars must undergo thorough analytical and bioanalytical characterisation. Biosimilars require sophisticated analytical techniques to evaluate structural, functional, and biological characteristics, in contrast to small-molecule generics, where chemical equivalency may be proven quite readily. These tests are necessary to verify that there are no clinically significant variations in the biosimilar's efficacy, safety, or purity.

2.1 Structural and Functional Characterization,

The development of biosimilars is predicated on structural characterization. Physicochemical characteristics and functional activity are compared with the reference biologic using a range of analytical techniques:

Chromatographic techniques (HPLC, UPLC) are employed to separate and analyse impurities, charge variations, and molecular sizes.

Mass spectrometry (MS) is a technique that accurately determines molecular weight and identifies post-translational changes like phosphorylation and glycosylation.

For conformational analysis and higher-order structural clarification, nuclear magnetic resonance, or NMR, is employed.

Secondary and tertiary protein structures are studied using Raman spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), and Circular Dichroism (CD).

Disulphide linkage analysis and peptide mapping are used to verify the integrity of the basic structure. Other important analytical techniques that aid in evaluating charge variations, size heterogeneity, and protein stability include polyacrylamide gel electrophoresis (PAGE), Western blotting, capillary zone electrophoresis (CZE), and isoelectric focussing (IEF).

To verify biological activity, functional characterisation is just as important as structure. Studies on receptor binding and potency are used to show that the biosimilar performs the same pharmacological function as the reference biologic.

2.2 Bioanalytical Techniques for PK/PD Research

During clinical development, biosimilars' pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity are assessed using bioanalytical techniques. For measuring biosimilars in biological matrices, ligand-binding assays (LBA) like enzyme-linked immunosorbent assays (ELISA) are frequently employed.

Specificity, selectivity, accuracy, precision, sensitivity, and stability in physiological settings are among the validation criteria.

Comparability studies employ both one-assay and two-assay methodologies. Whereas the two-assay technique creates distinct assays for the biosimilar and reference product, the one-assay approach employs a single validated procedure for both. The decision is based on regulatory criteria and assay performance.

Additionally, immunogenicity testing is incorporated into bioanalytical evaluations to guarantee the detection and measurement of putative anti-drug antibodies (ADAs). These investigations are essential for figuring out whether biosimilars cause immune reactions that differ from those of their reference products.

The development of biosimilars is therefore based on analytical and bioanalytical problems. For biosimilarity to be established and for patients to receive safe and effective treatment alternatives, strong methodology, rigorous validation, and regulatory compliance are necessary.

Medicinal monitoring of biosimilars

The long-term safety and effectiveness of biosimilars following their introduction into clinical practice are greatly dependent on pharmacovigilance. In order to identify uncommon or delayed side effects that might not be noticeable during pre-approval clinical trials, ongoing monitoring is crucial due to the complexity of biologics and the possibility of immunogenicity.

3.1 Plans for Risk Management

To proactively identify, evaluate, and reduce the risks related to biosimilars, manufacturers must put risk management plans (RMPs) into place. These plans contain established procedures for keeping an eye on safety indicators, controlling hazards that have been discovered, and informing medical experts about safety.

3.2 Monitoring of Safety Signals

Post-marketing clinical research, adverse event databases, and spontaneous reporting systems are used to closely monitor safety signals, such as unanticipated adverse responses or loss of efficacy. In clinical use, this kind of monitoring guarantees that biosimilars stay comparable to their reference drugs and aids in the establishment of a real-world safety profile.

3.3 Traceability and Immunogenicity

Because biosimilars are protein-based and structurally complicated, immunogenicity is still a major problem. Immune responses may be triggered by even small differences in production. Thus, to identify immunogenic occurrences, strong pharmacovigilance systems are needed. Additionally, traceability is essential; in order to support efficient safety investigations, adverse occurrences must be precisely connected to the particular biosimilar product and batch.

3.4The Function of Collaboration and Patient Registries

Important long-term data on biosimilar performance in various populations can be obtained via patient registries and observational studies. Working together, regulatory bodies, producers, medical professionals, and patients can improve the calibre of pharmacovigilance efforts and guarantee prompt detection of safety issues.[41,42,43,44,45]



CONCLUSION

By providing clinically comparable substitutes for original biologics with possible advantages in accessibility and affordability, biosimilars constitute a substantial breakthrough in contemporary treatments. Unlike traditional generics, their creation necessitates thorough preclinical, clinical, and analytical assessments to show structural, functional, pharmacokinetic, and immunogenicity similarities.

Thorough recommendations that emphasise a sequential approach, encompassing quality characterisation, comparability studies, PK/PD profiling, efficacy, and long-term pharmacovigilance, have been established by international regulatory authorities like the U.S. FDA, EMA, and WHO. These frameworks promote worldwide harmonisation of biosimilar approvals while guaranteeing patient safety and therapeutic equivalency. Biosimilars are essential in oncology because they increase access to treatment in high-cost therapeutic areas including colorectal cancer, breast cancer, and lymphoma, where biologics like bevacizumab, rituximab, and trastuzumab are the most common. Oncology biosimilars maintain comparable efficacy and safety to reference biologics while considerably lowering healthcare costs, according to evidence from clinical trials and real-world data. Therefore, biosimilars promise greater equity in the delivery of cancer care globally in addition to bolstering healthcare sustainability.

REFERENCES

1. Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars, 2011 Mar 15; 1-1.
2. Patel PK, King CR, Feldman SR. Biologics and biosimilars. Journal of Dermatological Treatment, 2015 Jul 4; 26(4): 299-302.
3. Misra A. Are biosimilars really generics?. Expert opinion on biological therapy, 2010 Apr 1; 10(4): 489-94.
4. Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar?. Journal of diabetes science and technology, 2011 May; 5(3): 741-54.
5. Geynisman DM, De Velasco G, Sewell KL, Jacobs I. Biosimilar biologic drugs: a new frontier in medical care. Postgraduate Medicine, 2017 May 19; 129(4): 460-70.
6. McCamish, M., & Woollett, G. (2013). The state of the art in the development of biosimilars. Clinical Pharmacology & Therapeutics, 91(3): 405–417. https://doi.org/10.1038/clpt.2011.328
7. Kuhlmann, M., & Covic, A. (2006). The protein science of biosimilars. Nephrology Dialysis Transplantation, 21(5): v4–v8. https://doi.org/10.1093/ndt/gfl474

8. Farhat, N., Al-Saedi, Z. H. F., & Saeed, R. M. (2022). Biosimilars: Current status and future perspectives. Frontiers in Bioengineering and Biotechnology, 10: 832059. https://doi.org/10.3389/fbioe.2022.832059
9. Poonia, N., Khatik, G. L., & Singhvi, G. (2023). Biosimilars: Development, regulatory challenges, and future perspectives. PLOS ONE, 18(9): e0292231. https://doi.org/10.1371/journal.pone.029223
10. Ratih, H. (2020). Biosimilars: A comprehensive review. Ubaya Repository. https://repository.ubaya.ac.id/39819/4/Ratih_Biosimilars.pdf
11. Kuhlmann, M., & Covic, A. (2016). Basic facts about biosimilars. Kidney and Blood Pressure Research, 30(5): 267–272. https://doi.org/10.1159/000093579
12. McCamish, M., & Woollett, G. (2013). The state of the art in the development of biosimilars. Clinical Pharmacology & Therapeutics, 91(3), 405–417. https://doi.org/10.1038/clpt.2011.328
13. Falconer, R. J., & Marlowe, C. K. (2011). Analytical techniques for assessing biosimilarity of therapeutic proteins. Journal of Chemical Technology & Biotechnology, 86(8): 915–922. https://doi.org/10.1002/jctb.2635
14. Ratih R, Asmari M, Abdel-Megied AM, Elbarbry F, El Deeb S. Biosimilars: Review of regulatory, manufacturing, analytical aspects and beyond. Microchemical Journal, 2021 Jun 1; 165: 106143.
15. Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, Liu J. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. In MAbs, 2018 May 19; 10(4): 678-691. Taylor & Francis.
16. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Reviews Drug Discovery, 2012 Jul; 11(7): 527-40.
17. Lee KH, Lee J, Bae JS, Kim YJ, Kang HA, Kim SH, Lee SJ, Lim KJ, Lee JW, Jung SK, Chang SJ. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. InMAbs, 2018 Apr 3; 10(3): 380-396. Taylor & Francis.
18. Chow SC, Song F, Bai H. Analytical similarity assessment in biosimilar studies. The AAPS journal, 2016 May; 18: 670-7.
19. Liu J, Eris T, Li C, Cao S, Kuhns S. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. BioDrugs, 2016 Aug; 30: 321-38.
20. Paek K, Kim GW, Ahn SY, Lim JH, Jung D, Kim S, Lee JH. Assessment of the molecular mechanism of action of SB3, a trastuzumab biosimilar. BioDrugs, 2019 Dec; 33: 661-71.
21. Lee KH, Lee J, Bae JS, Kim YJ, Kang HA, Kim SH, Lee SJ, Lim KJ, Lee JW, Jung SK, Chang SJ. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product. InMAbs, 2018 Apr 3; 10(3): 380-396. Taylor & Francis.
22. Chow SC, Song F, Bai H. Analytical similarity assessment in biosimilar studies. The AAPS journal, 2016 May; 18: 670-7.
23. Liu J, Eris T, Li C, Cao S, K
24. Haustein, R., Házi, F., Abud, L., Darba, J., Brixner, D., Afonso, M., ... & Dilla, T. (2014). Saving money with biosimilars: is this possible? PM&R, 6(S4): S3–S12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5814534/
25. Lucero, M., Wang, J., & Basu, S. (2022). Understanding the current landscape of biosimilar interchangeability in the US. Expert Opinion on Biological Therapy, 22(11): 1251–1260. https://www.tandfonline.com/doi/full/10.1080/14712598.2022.2112664
26. GABI. (2023). Biosimilars in the EU – 2023 update. Generics and Biosimilars Initiative Journal. https://www.gabionline.net
27. Tischer, B., & Machacek, C. (2019). Regulatory approval of biosimilars: a global snapshot. Drug Discovery Today, 24(10): 1963–1967. https://www.sciencedirect.com/science/article/pii/S1359644619301412
28. European Medicines Agency. (2005). Guideline on similar biological medicinal products. EMA/CHMP/437/04. Retrieved from https://www.ema.europa.eu/en
29. European Medicines Agency. (2014). Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. EMA/CHMP/BMWP/403543/2010.
30. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. Silver Spring, MD: U.S. FDA. Retrieved from https://www.fda.gov
31. U.S. Food and Drug Administration. (2018). Considerations in demonstrating interchangeability with a reference product: Guidance for industry. Silver Spring, MD: U.S. FDA.
32. World Health Organization. (2009). Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: WHO. Retrieved from https://www.who.int
33. Central Drugs Standard Control Organization & Department of Biotechnology (India). (2016). Guidelines on similar biologics: Regulatory requirements for marketing authorization in India. New Delhi: Ministry of Health and Family Welfare, Government of India.
34. Tabernero, J., Vyas, M., Giuliani, R., Arnold, D., Cardoso, F., Casali, P. G., … Douillard, J. Y. (2019). Biosimilars in oncology: A critical review of regulatory, clinical, and economic factors. Cancer Treatment Reviews, 72: 41–49. https://doi.org/10.1016/j.ctrv.2018.11.003

35. https://onlinelibrary.wiley.com/doi/full/10.1002/cnr2.1720
36. Falconer, R. J., & Marlowe, C. K. (2011). Analytical techniques for assessing biosimilarity of therapeutic proteins. Journal of Chemical Technology & Biotechnology, 86(8): 915–922. https://doi.org/10.1002/jctb.2635
37. Singleton, C. (2014). Mass spectrometry in the analysis of biosimilars. ResearchGate. Retrieved from https://www.researchgate.net/publication/264394334
38. Nakajima, T., Fukuda, M., & Harazono, A. (2019). Advanced protein characterization methods for biosimilar development. Journal of Bioscience and Bioengineering, 128(6): 635–643. https://doi.org/10.1016/j.jbiosc.2019.05.005
39. McCamish, M., & Woollett, G. (2013). The state of the art in the development of biosimilars. Clinical Pharmacology & Therapeutics, 91(3): 405–417. https://doi.org/10.1038/clpt.2011.328
40. Farhat, N., Al-Saedi, Z. H. F., & Saeed, R. M. (2022). Biosimilars: Current status and future perspectives. Frontiers in Bioengineering and Biotechnology, 10: 832059. https://doi.org/10.3389/fbioe.2022.832059
41. McCamish, M., & Woollett, G. (2013). The state of the art in the development of biosimilars. Clinical Pharmacology & Therapeutics, 91(3): 405–417. https://doi.org/10.1038/clpt.2011.328
42. Farhat, N., Al-Saedi, Z. H. F., & Saeed, R. M. (2022). Biosimilars: Current status and future perspectives. Frontiers in Bioengineering and Biotechnology, 10: 832059. https://doi.org/10.3389/fbioe.2022.832059
43. Tabernero, J., Vyas, M., Giuliani, R., Arnold, D., Cardoso, F., Casali, P. G., … Douillard, J. Y. (2019). Biosimilars in oncology: A critical review of regulatory, clinical, and economic factors. Cancer Treatment Reviews, 72: 41–49. https://doi.org/10.1016/j.ctrv.2018.11.003
44. World Health Organization. (2009). Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: WHO. Retrieved from https://www.who.int
45. European Medicines Agency. (2017). Good pharmacovigilance practices (GVP) for biological medicinal products. EMA. Retrieved from https://www.ema.europa.eu